Pediatrix Medical Group (NYSE:MD) Upgraded at StockNews.com

Pediatrix Medical Group (NYSE:MD) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Wednesday.

A number of other brokerages have also recently commented on MD. Truist Financial lifted their price objective on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Jefferies Financial Group lifted their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. UBS Group lifted their price target on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Finally, Mizuho lifted their price objective on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $16.10.

Pediatrix Medical Group Stock Performance

Shares of NYSE:MD opened at $14.17 on Wednesday. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41. The stock has a market capitalization of $1.22 billion, a P/E ratio of -4.63, a PEG ratio of 2.10 and a beta of 1.57. The firm has a fifty day simple moving average of $13.93 and a two-hundred day simple moving average of $10.68. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. During the same period last year, the company posted $0.29 EPS. The business’s revenue was up .9% on a year-over-year basis. On average, analysts expect that Pediatrix Medical Group will post 1.26 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now directly owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This represents a 16.60 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by company insiders.

Institutional Trading of Pediatrix Medical Group

Large investors have recently made changes to their positions in the business. Rubric Capital Management LP boosted its holdings in Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after buying an additional 7,241,400 shares in the last quarter. Dana Investment Advisors Inc. grew its holdings in Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after purchasing an additional 455,785 shares during the period. Weiss Asset Management LP raised its stake in shares of Pediatrix Medical Group by 50.5% during the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after buying an additional 306,143 shares during the period. Cubist Systematic Strategies LLC lifted its position in shares of Pediatrix Medical Group by 639.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after buying an additional 251,072 shares in the last quarter. Finally, ClariVest Asset Management LLC acquired a new stake in Pediatrix Medical Group in the 2nd quarter valued at $1,721,000. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.